iBB

Microfluidic paper-based analytical devices (μPADs) have emerged in the last years as an ideal technology to develop Point-Of-Care testing. In an article just published in Analytical Biochemistry, Sónia Ruivo, Ana Azevedo and Miguel Prazeres from BERG-iBB describe a μPADs immunoassay for detection of D-dimer, a blood native biomarker helpful in diagnosing diseases like disseminated intravascular coagulation, deep vein thrombosis and pulmonary embolism. The μPADs were successfully used to detect concentrations of D-dimer in simulated plasma samples as low as 15 ng/mL. The tests were further adapted to yield positive results only for samples with D-dimer concentrations above the clinically relevant threshold range of 250–500 ng/mL. Click on title to learn more.